Seroneutralisation & Haemagglutination

Texcell develops and validates seroneutralisation assays for vaccine assessment.

We have broad, in-depth experience in performing seroneutralisation during clinical trials (Phases I to IV). For example, we performed seroneutralisation assays for 3 subtypes of poliovirus during a phase IV clinical trial, on more than 3000 patient samples.

TITRATION METHODS ALREADY VALIDATED FOR THE FOLLOWING HUMAN VIRUSES:

Adenovirus 5 adeno 5 Adenoviridae Adenovirus
Herpes simplex virus 1 HSV-1 HerpesViridae Simplexvirus
Vaccine Vaccine Poxviridae Orthopoxvirus
Human rhinovirus HRV Picornaviridae Rhinovirus
Poliovirus (sabin strain) Polio Picornaviridae Enterovirus
Hepatitis A virus HAV Picornaviridae Hepatovirus
Human immunodeficiency virus type 1 HIV 1 Retroviridae Lentivirus
Parainfluenza 3 virus Para3 Paramyxoviridae Paramyxovirus
Sindbis virus Sindbis Togaviridae Alphavirus
Reovirus type 3 REO3 Reoviridae Orthoreovirus

TITRATION OF ANTIBODIES AGAINST INFLUENZA VACCINE (HIA):

Texcell offers the titration of antibodies against influenza vaccine in patient samples from clinical trials. As recommended by WHO, we perform titration using a haemagglutination inhibition assay (HIA). Depending on the WHO’s annual recommendations, we offer different strains in collaboration with national flu reference centres.

e.g.: in the winter of 2005 for the northern hemisphere, the vaccines contained the following strains:

  • A/New Caledonia/20/99(H1N1)-like virus
  • A/California/7/2004(H3N2)-like virus a
  • B/Shanghai/361/2002-like virus b